Clinical trial · Interventional
In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?
NCT03174912CI-TRIAL-00027981completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Investigators aimed to evaluate the performance of The European Organization for Research and Treatment of Cancer(EORTC) and the Spanish Urology Association for Oncological Treatment(CUETO) risk tables on all non-muscle invasive bladder cancer patients(NMIBC), and those not treated with BCG and treated with BCG separately.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Disease Progression | — | UNRESOLVED | — |
| Recurrent Bladder Cancer | Malignant Bladder Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intravesical BCG instillation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Group 1
- description
- Whole patient group (patients not treated with BCG and patients treated with BCG)
- interventionNames
- Procedure: Intravesical BCG instillation
- type
- NO_INTERVENTION
- label
- Group 2
- description
- Patients not treated with BCG
- type
- ACTIVE_COMPARATOR
- label
- Group 3
- description
- Patients treated with BCG
- interventionNames
- Procedure: Intravesical BCG instillation
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * primary or recurrent bladder cancer * non-muscle invasive bladder cancer * at least 60 months follow-up period if progression was not determined. Exclusion Criteria: * primary CIS, * muscle-invasive disease after second look TUR-BT * non-urothelial carcinoma of the bladder, * concomitant upper urinary tract tumor, * not able to contacted for whatever reason
References
Publications (2)
- RESULTXylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS, Lotan Y, Trinh QD, Karakiewicz PI, Holmang S, Scherr DS, Zerbib M, Vickers AJ, Shariat SF. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer. 2013 Sep 17;109(6):1460-6. doi: 10.1038/bjc.2013.372. Epub 2013 Aug 27. PMID 23982601
- RESULTXu T, Zhu Z, Zhang X, Wang X, Zhong S, Zhang M, Shen Z. Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models. Urology. 2013 Aug;82(2):387-93. doi: 10.1016/j.urology.2013.04.007. Epub 2013 Jun 10. PMID 23759377